Mirum Pharmaceuticals Inc is a pioneering biopharmaceutical firm dedicated to creating innovative treatments for rare and orphan diseases. With a focus on liver disorders, its flagship product, LIVMARLI, is an oral medication aimed at combating progressive familial intrahepatic cholestasis, Alagille syndrome, and biliary atresia. Additionally, Mirum is advancing Volixibat, targeting adult primary sclerosing cholangitis and primary biliary cholangitis. Founded in 2018, Mirum is based in Foster City, California, demonstrating a commitment to addressing unmet medical needs in the realm of liver disease.
Insiders continue to scoop up Under Armour and W.R. Berkley shares, and a public offering of International Tower Hill Mines shares prompted huge insider purchases as well.
